| Literature DB >> 32675800 |
Anying Li1, Wei Huang1, Qiong Yang1, Liping Peng1, Qiang Liu2.
Abstract
BACKGROUND The C677T polymorphism of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism has been associated with hypertension and coronary heart disease, but its relationship with carotid artery remains unknown. This study aimed to investigate the association between the C677T polymorphism of the MTHFR gene in patients with confirmed carotid artery atherosclerosis. MATERIAL AND METHODS This retrospective study included 210 patients with carotid artery atherosclerosis (the patient group) and 210 controls (the control group). Color Doppler ultrasound was used to identify carotid artery intimo-medial thickness and atherosclerotic plaques. Sanger sequencing using the polymerase chain reaction (PCR) was used to detect the MTHFR C677T gene polymorphism. Systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), glycosylated hemoglobin (HbA1c), and other laboratory indicators were measured. RESULTS SBP, DBP, FPG, TC, LDL-C, HbA1c, and intimo-medial thickness were significantly increased in the patient group compared with the control group, and HDL-C was significantly lower. The allele frequencies of the C667T locus of MTHFR gene were significantly different between the two groups (P<0.05), and the TT genotype and the T allele frequencies in the patient group were higher than in the control group. Logistic regression analysis showed that SBP, TC, LDL-C, and the C667T MTHFR gene polymorphism were risk factors for carotid artery atherosclerosis. CONCLUSIONS The C677T polymorphism of the MTHFR gene was expressed in patients with carotid artery atherosclerosis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32675800 PMCID: PMC7387044 DOI: 10.12659/MSM.920320
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Analysis of general data and biochemical indicators.
| Patients group | Control group | |||
|---|---|---|---|---|
| Agen | 65.54±9.23 | 64.83±10.41 | 0.740 | 0.460 |
| Gender (M/F) | 103/107 | 106/104 | 0.086 | 0.770 |
| Smoking (%) | 138 (65.71) | 124 (59.05) | 1.471 | 0.241 |
| Hypertension (%) | 121 (57.62) | 133 (63.33) | 1.827 | 0.087 |
| Diabetes (%) | 118 (56.19) | 125 (59.52) | 1.581 | 0.281 |
| Hcy (μmol/L) | 12.4±2.14 | 11.2±3.01 | 1.281 | 0.162 |
| BMI (Kg/cm2) | 25.46±3.57 | 24.87±2.93 | 1.851 | 0.065 |
| SBP (mmHg) | 143.08±19.41 | 130.74±18.02 | 6.752 | <0.001 |
| DBP (mmHg) | 88.24±13.93 | 84.68±11.58 | 2.848 | 0.005 |
| FPG (mmol/L) | 5.81±1.76 | 4.93±0.91 | 6.436 | <0.001 |
| TG (mmol/L) | 1.62±0.81 | 1.53±0.73 | 1.196 | 0.232 |
| TC (mmol/L) | 4.71±1.10 | 4.38±1.14 | 3.019 | 0.003 |
| HDL-C (mmol/L) | 1.26±0.53 | 1.57±0.59 | 5.664 | <0.001 |
| LDL-C (mmol/L) | 2.72±0.83 | 2.39±0.67 | 11.742 | <0.001 |
| HbA1c (%) | 6.92±1.54 | 6.24±1.37 | 4.781 | <0.001 |
Figure 1The MTHFR gene polymorphism sequencing results (A) MTHFR wild type; the 677CC genotype. (B) MTHFR heterozygous mutant; the 677CT genotype. (C) MTHFR homozygous mutant; the 677TT genotype.
Hardy-Weinberg equilibrium test for polymorphic loci.
| Group | Genotype | Alleles | χ2 | |||||
|---|---|---|---|---|---|---|---|---|
| CC (%) | CT (%) | TT (%) | C (%) | T (%) | ||||
| Control | C/T | 98 (23.33) | 179 (42.62) | 143 (34.05) | 375 (44.64) | 465 (55.36) | 7.966 | >0.05 |
| All cases | C/T | 112 (21.87) | 172 (44.23) | 137 (31.92) | 359 (41.81) | 451 (59.25) | ||
Comparison of MTHFR C667 allele frequency and genotype frequency.
| Genotype | χ2 | Alleles | χ2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CC (%) | CT (%) | TT (%) | C (%) | T (%) | |||||
| Patients | 40 (19.05) | 68 (32.38) | 102 (48.57) | 148 (35.24) | 272 (64.76) | 30.06 | <0.01 | ||
| Control | 58 (27.62) | 111 (52.86) | 41 (19.52) | 227 (12.00) | 193 (88.00) | ||||
Comparison of MTHFR C667 allele frequency and genotype frequency.
| Genotype | χ2 | Alleles | χ2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CC (%) | CT (%) | TT (%) | C (%) | T (%) | |||||
| Stable plaque | 12 (14.46) | 44 (53.01) | 27 (32.53) | 68 (40.96) | 98 (59.04) | 3.943 | 0.047 | ||
| Unstable plaque | 28 (22.05) | 24 (18.90) | 75 (59.05) | 80 (31.50) | 174 (68.50) | ||||
| Folate level (ng/L) | 7.45±2.34 | 7.25±1.21 | 6.94±1.31 | 6.81±1.28 | 6.79±1.31 | 4.129 | 0.129 | ||
| B12 (pg/L) | 235.25±137.21 | 203.51±136.25 | 211.25±129.55 | 165.85±128.58 | 166.95±130.55 | 2.142 | 0.081 | ||
| Hcy (μmol/L) | 24.24±2.04 | 23.24±2.15 | 23.35±2.21 | 22.24±2.04* | 20.85±1.92 | 3.212 | 0.522 | ||
Regression analysis of CAS risk factors.
| Variables | β | SE | Wald χ2 | p | OR | 95% CI |
|---|---|---|---|---|---|---|
| Hypertension (mmHg) | 0.478 | 0.213 | 6.271 | >0.05 | 1.621 | 0.928–2.187 |
| Diabetes (mmol/L) | 0.481 | 0.211 | 6.382 | >0.05 | 1.438 | 0.791–2.381 |
| TC (mmol/L) | 0.517 | 0.301 | 7.238 | >0.05 | 1.582 | 0.892–2.193 |
| TG (mmol/L) | 0.523 | 0.249 | 6.389 | >0.05 | 1.639 | 0.987–2.357 |
| HDL-C (mmol/L) | 0.486 | 0.252 | 7.393 | >0.05 | 1.538 | 0.892–2.452 |
| LDL-C (mmol/L) | 0.472 | 0.262 | 6.938 | >0.05 | 1.638 | 0.731–2.324 |
Logistic regression analysis of risk factors for carotid atherosclerosis.
| B | SE | Wals | P | OR | 95% CI | |
|---|---|---|---|---|---|---|
| SBP (mmol/L) | 1.762 | 0.543 | 8.745 | 0.001 | 3.514 | 1.372–4.826 |
| TC (mmol/L) | 1.638 | 0.509 | 7.804 | 0.006 | 2.376 | 1.408–3.822 |
| LDL-C (mmol/L) | 1.204 | 0.463 | 5.317 | 0.017 | 1.925 | 1.124–3.017 |
| MTHFR polymorphism | 2.043 | 0.628 | 9.737 | 0.001 | 6.143 | 3.872–11.526 |